['diabetes mellitus', 'diabetic retinopathy', 'macular edema']
['ranibizumab 0.5mg', 'thr-317 8mg', 'sham injection']

        Inclusion Criteria:

          -  Male or female aged 18 years or older

          -  Type 1 or type 2 Diabetes Mellitus

          -  CI-DME with central subfield thickness of ≥ 320μm on Spectralis® SD-OCT or ≥ 305μm on
             non Spectralis SD-OCT, in the study eye

          -  Anti-vascular endothelial growth factor (anti-VEGF) treatment naïve study eye, or poor
             or no response to prior treatment with ranibizumab in the study eye

          -  Reduced vision primarily due to DME, with BCVA ≤ 72 and ≥ 23 ETDRS letter score (≤
             20/40 and ≥ 20/320 Snellen equivalent) in the study eye

          -  Non-proliferative diabetic retinopathy of any stage in the study eye

          -  Written informed consent obtained from the subject prior to screening procedures

        Exclusion Criteria:

          -  Concurrent disease in the study eye, other than CI-DME, that could compromise BCVA,
             require medical or surgical intervention during the study period or could confound
             interpretation of the results

          -  Previous confounding treatments / procedures, or their planned / expected use during
             the study period for up to 30 days after the last administration of study treatment

          -  Any active ocular / intraocular infection or inflammation in either eye

          -  Aphakic study eye

          -  Poorly controlled Diabetes Mellitus

          -  Uncontrolled hypertension

          -  Pregnant or lactating female, or female of child-bearing potential not utilising an
             adequate form of contraception, or male of reproductive potential not utilising
             contraception
      